Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Myopia
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Prospective, open label, 12 month follow up studyMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 8 years and 125 years
- Gender
- Both males and females
Description
This clinical study has two phases: prospective and retrospective. Prospective Phase - evaluates the post-market long-term effectiveness and safety of the Paragon CRT® 100 Contact Lenses, for temporary myopic refractive power reduction with minimum 12-month period follow-up. Retrospective phase - ev...
This clinical study has two phases: prospective and retrospective. Prospective Phase - evaluates the post-market long-term effectiveness and safety of the Paragon CRT® 100 Contact Lenses, for temporary myopic refractive power reduction with minimum 12-month period follow-up. Retrospective phase - evaluates the post-market long-term safety of the Paragon CRT® 100 Contact Lenses, for temporary myopic refractive power reduction.
Tracking Information
- NCT #
- NCT04187599
- Collaborators
- TigerMed
- Investigators
- Principal Investigator: Jiang Jun, MD The Affiliated Eye Hospital of Wenzhou Medical University Principal Investigator: Qu Xiao Mei, MD Eye & ENT Hospital of Fudan University Principal Investigator: Yang Zhi Kuan, MD Changsha Aier Eye Hospital Principal Investigator: Li Li Hua, MD Tianjin Eye Hospital
Get Well Soon